Skip to main content

Table 1 Patient baseline characteristics (number = 819).

From: Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy

Characteristic Number %
Age at diagnosis   
   < 50 290 35.4
   > 50 529 64.6
T stage   
   T1 613 74.8
   T2 195 23.8
   T3 11 1.4
Number of positive nodes   
   0 586 71.6
   1-3 219 26.7
   > 4 10 1.2
   No nodes sampled 4 0.5
Grade   
   1 84 10.3
   2 431 52.6
   3 300 36.6
   Unknown 4 0.5
ER or PR positive 656 80.1
HER2 positive 109 13.3
LVI present 137 16.7
Hormonal therapy received 553 67.5
Chemotherapy received 389 47.5
Trastuzumab therapy received (if HER2 positive, Number = 108) 28 25.9
Margins   
   Close or positive 27 3.3
   Negative 791 96.6
   Unknown 1 0.1
Constructed subtype   
   HR+/HER2+ 574 70
   HR+HER2+ 57 7
   HR-/HER2+ 51 6.2
   HR-/HER2- 94 11.5
   Unknown 43 5.3
  1. ER, estrogen receptor; HER2, human epidermal growth receptor 2; LVI, lymphovascular space invasion; PR, progesterone receptor.